Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2023 Earnings Call Transcript

Dwight Egan: Thank you, Brian. Before opening for Q&A, I want to take a moment to extend our thanks to all of our shareholders as well as the whole Co-Dx family and employees, distributors and consultants. We look forward to talking with you again after the next quarter. We will now take calls from our analysts, operator.

Operator: [Operator Instructions] And we do have a question from Jay Montgomery from HC Wainwright.

Unidentified Analyst : Hi. Thank you for the call today. So I was just wanting to know, how soon could the FDA complete the review of your EUA submission once it’s submitted? Do you have any idea?

Dwight Egan: Thank you for the question. The FDA has their own timeline. So we don’t really have estimation of what kind of time they’re going to take to review the application. All we can tell you is that we believe our application will be is a very solid application when we make it. And so we’re enthused to be to that milestone, but as to timetable for the FDA to respond. We don’t have a way to predict them.

Unidentified Analyst : Okay. And would you be able to provide an estimate of the initial amount of the order size once the product is launched?

Dwight Egan: That’s an interesting question. We don’t have any way and we haven’t provided any guidance, as we said in our script, that there’s no guidance that we’re providing. So we don’t have information to provide to the public currently on orders that would be placed. We, I mean, the product is now on the market. So we can’t take orders at this point anyway, no, yes.

Unidentified Analyst : All right. And so primary market then, I mean, you’re looking at more sort of, like nursing homes, that sort of market or –?

Dwight Egan: Yes, the markets that give us an opportunity to have significant throughput from each device placed our areas of first concern in our marketing plans, and that includes things like skilled nursing facilities. And there are lots of those around the country that is one of our primary targets, they have a very strong need to continue to test patients and employees for COVID. And of course, as we increase the menu over time, they’re a prime market for that as well. But the point-of-care where there’s a larger opportunity for throughput per device is our initial attraction from a marketing standpoint.

Operator: And this concludes the question and answer session as well as the call. Thank you so much for attending today’s presentation. And you may now disconnect your lines.